The 'lupus anticoagulant'1 and antibodies to cardiolipin2 have been associated with an increased incidence of both venous and arterial thromboses, particularly cerebral occlusions,3 in patients with systemic lupus erythematosus (SLE), other autoimmune disorders, 3a and after the administration of certain drugs.4 An increased frequency of these antiphospholipid antibodies has also been associated with pulmonary hypertension in SLE.s A close correlation between the lupus anticoagulant and anticardiolipin antibodies has been shown, 6 and the subject has recently been reviewed.7 8 In a retrospective study of patients with high anticardiolipin antibody we have observed six patients with recurrence of thrombosis several weeks after cessation of warfarin. Five patients had SLE. The sixth patient had some features of an autoimmune disease. Four patients were female, two were male, aged 17 to 43 years. All of them were previously maintained on warfarin for three months to three years because of deep vein thrombosis (DVT) or Angiography showed normal coronary vessels, and the patient was restarted on anticoagulant therapy. The patient demonstrated the 'lupus anticoagulant' and a high titre of anticardiolipin antibodies in serum at the time of the coronary occlusion. CASE 6 This 44-year-old West Indian female first developed pleuritic chest pain at the age of 35 years, followed three years later by a deep venous thrombosis of the left leg. This was treated with anticoagulant therapy for two months (warfarin). The following year she developed polyarthralgias, polymyalgias, Raynaud's phenomenon, skin rash, and mouth ulcers, and a diagnosis of SLE was made on the basis of the clinical symptomatology and confirmatory blood findings. At age 40 a right sided deep venous thrombosis occurred, and she was maintained on anticoagulants on this occasion. After two years they were discontinued because of a gastrointestinal haemorrhage. Two months later a further right deep vein thrombosis occurred, followed by pulmonary embolisation, which subsequently became infected.
Other has been shown, however, in our laboratories that the latter is not operating in our patients with SLE and venous thromboses. '6 Recently the presence of anticardiolipin antibodies has been shown to be associated with a greatly increased risk of venous and arterial thrombosis.2 This antibody is similar if not identical to the antiphospholipid antibody confusingly known as the 'lupus anticoagulant' -also regarded to be a risk factor for thrombosis.'
The present report suggests that anticoagulation is distinctly important in preventing recurrences of thrombosis in this group of patients and that this treatment should be used indefinitely in patients showing high titres of anticardiolipin antibodies. The quantitative estimation of the anticardiolipin antibodies appears to represent a significant advance in the assessment of the risk of recurrent venous or arterial thrombosis in these patients, and the importance of their evaluation is also supported by the recent demonstration of their association with mesenteric, 16 placental,17 and other large vessel arterial occlusions. '8 We would like to thank Miss Selina Lydon for secretarial assistance. reading it and both they and their consultants will find it a useful reference work. 
